ConductScience.org, home

Comparison · NCT04999020-df01b30b

RCP: Ravulizumab vs RCP: Placebo: Number of Participants Who Received Acute Rescue Therapy With Standard DM Treatment

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. RCP: Ravulizumab vs RCP: Placebo: Number of Participants Who Received Acute Rescue Therapy With Standard DM Treatment. Trial comparisons, record NCT04999020-df01b30b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04999020-df01b30b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.07690.02140.241wilson
Risk in group 200.00000000000000002780.242wilson
Risk difference, group 1 minus group 20.0769-0.1720.241newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on RCP: Ravulizumab than on RCP: Placebo13from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1RCP: RavulizumabParticipants received a loading dose of ravulizumab on Day 1 followed by a maintenance dose at Week 2 and then ravulizumab once every 8 weeks (Q8W) during the 26-week RCP.226OG000
Group 2RCP: PlaceboParticipants received placebo on Day 1, and Weeks 2, 10, and 18 during the 26-week RCP.012OG001

Outcome

Type
SECONDARY
Title
Number of Participants Who Received Acute Rescue Therapy With Standard DM Treatment
Description
Acute rescue therapy with standard DM treatment included an increased dose of a medication that was being taken for DM or the initiation of a new DM treatment (glucocorticoid and/or immunosuppressive/immunomodulatory therapy \[ISTs\]). Data are presented for the number of participants who received acute rescue therapy with standard DM treatment.
Time frame
Baseline through Week 26
Population
Randomized Set, which included all randomized participants grouped by randomized treatment group.

Source ClinicalTrials.gov

Trial

Title
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
NCT number
NCT04999020
Phases
PHASE2, PHASE3
Conditions
Dermatomyositis
Interventions
Ravulizumab, Placebo
Lead sponsor
Alexion Pharmaceuticals, Inc.
Results first posted
2024-12-06

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04999020-df01b30b